There have been five randomized clinical trials, Cai et al., 2022 [31], Elkind-Hirsch et al., 2021 [32], Javed et al., 2019 [33], Tan et al., 2022 [34], and Zhang et al., 2022 [35] that used SGLT2 inhibitors in women with PCOS and examined clinical outcomes, published as of end of year 2023. This evidence concerns the gene SLC5A2 and polycystic ovary syndrome.